Market Cap: $56.06M
TI
Talphera, Inc.
TLPH
NASDAQ (NASDAQ Global Market)USD
Market Cap: $56.06M
Talphera (Ticker: TLPH) makes significant strides in its clinical research, marking a crucial milestone in the development of alternative anticoagulants for Continuous Renal Replacement Therapy (CRRT)…
Talphera Advances Critical Anticoagulation Research for Renal Therapy Talphera, Inc., a specialty pharmaceutical company located in San Mateo, California, is making significant strides in critical car…
Talphera Sets the Stage for the Future of Continuous Renal Replacement Therapy Talphera, Inc., a specialty pharmaceutical company based in San Mateo, California, prepares for a significant virtual inv…
Talphera Prepares for Insightful Discussion on Innovative Renal Therapies Talphera, Inc., a San Mateo-based specialty pharmaceutical company, is set to host a virtual investor and analyst event on Mar…
Talphera Makes Significant Progress in NEPHRO-CRRT Study Enrollment Talphera, Inc., a specialist pharmaceutical company, reaches a pivotal milestone in its NEPHRO-CRRT registrational study, having suc…
Talphera Achieves Milestone in NEPHRO-CRRT Study Enrollment Talphera, Inc. has reached a significant milestone in its NEPHRO-CRRT registrational study, successfully enrolling 35 out of the targeted 70…
Talphera Advances CRRT Study Amid Regulatory Collaboration Talphera, Inc., a specialized pharmaceutical company focused on developing innovative therapies for medical settings, announces a major miles…
Talphera tightens content requirements for accurate external summaries Talphera is updating its communications protocols after a recent exchange highlights gaps in how outside parties request company-…
Talphera flags need for full source to ensure accurate external communications Talphera is informing correspondents that it cannot produce a faithful company‑specific summary from an incomplete prompt…
Talphera's Strategic Position in the Evolving Logistics Sector As the logistics sector grapples with post-pandemic recovery, Talphera remains at the forefront of addressing the challenges and opportun…
Talphera Prepares for Key Earnings Release Amid Strategic Growth Focus Talphera is set to announce its quarterly earnings on November 12, 2025, in a highly anticipated report that will provide insight…
Talphera's Earnings Announcement: A Crucial Moment for Strategic Insights As Talphera (NASDAQ:TLPH) prepares to announce its quarterly earnings on November 12, 2025, stakeholders are keenly focused on…
Strategic Board Appointment Signals Growth for Talphera, Inc. Talphera, Inc., a notable player in the specialty pharmaceutical sector, announces the appointment of Joe Todisco, CEO of CorMedix Inc., t…
Talphera Welcomes New Board Member Amid Strategic Partnership with CorMedix Talphera, Inc., a San Mateo-based specialty pharmaceutical company, announces the appointment of Joe Todisco, CEO of CorMedi…
Talphera Advances Clinical Trial for Niyad™ Amid Growing Enrollment Talphera, Inc., a specialty pharmaceutical company, announces significant progress in its pivotal NEPHRO CRRT clinical trial, having…
Talphera Advances Clinical Trial for Niyad™ in Renal Replacement Therapy Talphera, Inc. makes noteworthy progress in its pivotal NEPHRO CRRT clinical trial, which is currently evaluating the efficacy…
Talphera Advances Clinical Trial for Niyad™ in Renal Replacement Therapy Talphera, Inc., a specialty pharmaceutical company focused on developing innovative therapies, announces a significant mileston…